Covance
Home About Covance Investor Relations News Careers Contact Us
Home > Financial Info > Press Releases
 Advanced Search
Take me to...
Find a service
Drug Development Services
Nonclinical
Clinical
Commercialization
Industries We Serve
Biotech
Environmental
Food & Dietary Supplements
Pharma
Research
Vaccines
Antibody Products Store
Volunteer for a Study
Investigators
Information Library
Animal Welfare
COVANCE DELIVERS SOLID 2Q 1999 RESULTS
Year-to-Date Net Revenues Up 21.4%, Net Income Up 22.2%

Princeton, NJ, July 20, 1999 — Covance Inc. (NYSE: CVD), one of the world's largest and most comprehensive drug development services companies, today announced solid financial results for the second quarter ended June 30, 1999. Management said that the Company delivered its target of $0.26/share for the second quarter, excluding one-time costs of $5.2 million ($3.1 million after tax) or $0.05/share associated with its proposed acquisition of Parexel International Corporation.

Net revenues for the second quarter of 1999 were $215.1 million, up 18.1% compared to $182.1 million for the second quarter of 1998. Year-to-date net revenues were $425.7 million, up 21.4% from $350.6 million for the same period in 1998. Covance posted revenue gains in its Early Development services segment, which includes preclinical and Phase I clinical trial services, of 12.3% in the second quarter and 13.7% year-to-date. The Company's Late-Stage Development services segment, comprised of clinical trials management and support services, grew 21.1% for the quarter and 25.4% year-to-date.

Operating income for the second quarter of 1999, excluding one-time acquisition-related costs, increased 16.1% to $28.2 million, or 13.1% of net revenues, compared to $24.3 million, or 13.3% of net revenues, for the second quarter of 1998. Year-to-date operating income, excluding one-time acquisition-related costs, was $52.4 million up 17.4% compared to $44.6 million for the same period in 1998.

Net income for the second quarter of 1999, excluding one-time acquisition-related costs, was $15.4 million or $0.26/diluted share, up 19.3% compared to $12.9 million or $0.22/diluted share for the second quarter of 1998. Year-to-date net income, excluding one-time acquisition-related costs, was $28.5 million or $0.48/diluted share, up 22.2% compared to $23.3 million or $0.40/diluted share for the same period in 1998.

"Consistently strong management of our balanced portfolio of services has enabled Covance to deliver another quarter of solid results, " said Chris Kuebler, Chairman and CEO of Covance. "For the first half of this year, our revenues and earnings growth exceeded 20% and we remain on track to achieve consensus earnings estimates throughout 1999."

The demand for high quality contract drug development services continues to increase as pharmaceutical companies strive to increase the number, quality, and commercial value of drugs emerging from their pipelines. As an experienced and trusted leader in the contract drug development field, Covance is well positioned to capitalize on these growth trends and to continue to deliver strong earnings growth for its shareholders. Management intends to continue to pursue niche acquisitions that will enhance Covance's drug development capabilities.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with 1998 revenues of $732 million, operations currently in 17 countries, and approximately 7,700 employees worldwide. Covance's purpose is to lead advancements in drug development through science, service, and shaping solutions. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through the Company's website at: www.covance.com. To listen to Covance's live internet broadcast of its second quarter earnings conference call, please click here.


Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business and financial performance are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts or multiple contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.
SEC Filings
Annual Reports
Quarterly Reports
Press Releases

                            COVANCE INC.
         INCOME STATEMENTS - INCLUDING MERGER-RELATED CHARGE
      FOR THE THREE AND SIX  MONTHS ENDED JUNE 30, 1999 AND 1998
             (Dollars in thousands, except per share data)
                            (UNAUDITED)
                         
                         Three Months Ended           Six Months Ended
                              June 30                       June 30
                          1998         1997         1998          1997

Net Revenues          $215,060     $182,089     $425,692      $350,598 

Costs and expenses:
Cost of revenue        140,906 	    119,338      282,336       232,066 
Selling, general &
 administrative expense 34,383 	     29,426 	  68,194        56,339 
Depreciation and
 amortization           11,567 	      9,023       22,792        17,577 
Merger-related costs	 5,249          -          5,249           -   
Total                  192,105      157,787      378,571       305,982 


Income from operations  22,955 	     24,302       47,121        44,616 

Other expense, net:
 Interest expense, net   2,419        1,808        4,405         3,503  
Other expense (income)     161           74           81           187 
Other expense, net       2,580 	      1,882        4,486         3,690 

Income before taxes and
 equity investee 
 results                20,375 	     22,420 	  42,635        40,926 

Taxes on income          8,168 	      9,388 	  17,280        17,248 

Equity investee loss (gain) -           164         -              358 

Net income             $12,207      $12,868      $25,355       $23,320 

Basic earnings per share $0.21 	      $0.22 	   $0.43         $0.40 

Weighted average shares
 outstanding-basic  58,751,478   57,953,563   58,657,220    57,864,438 

Diluted earnings per
 share                   $0.21 	      $0.22 	   $0.43         $0.40 

Weighted average
 shares outstanding -
 diluted            59,348,559    58,457,280   59,600,313   58,290,610 



                             COVANCE INC.
                              PROFORMA*	
          INCOME STATEMENTS - EXCLUDING MERGER-RELATED CHARGE
       FOR THE THREE AND SIX  MONTHS ENDED JUNE 30, 1999 AND 1998
            (Dollars in thousands, except per share data)
 
 
                            Three Months Ended                Six  Months Ended
                                 June 30                            June 30
                                1999 *          1998            1999*       1998
								  
								  
Net revenues                  $215,060      $182,089         $425,692   $350,598 
	
 Costs and expenses:						
  Cost of revenue              140,906       119,338          282,336    232,066 
  Selling, general &  
   administrative expense       34,383        29,426           68,194     56,339 
	   
  Depreciation 
   and amortization             11,567         9,023           22,792     17,577 
	 
 Total                         186,856       157,787          373,322    305,982 
 
 
 Income from operations         28,204        24,302           52,370     44,616 
 
 
 
Other expense, net: 
 Interest expense, net           2,419         1,808            4,405      3,503  

Other expense                      161            74               81        187 
Other expense, net               2,580         1,882            4,486      3,690 


Income before taxes and 
 equity investee results        25,624        22,420           47,884     40,926 
								
Taxes on income                 10,267         9,388           19,379     17,248
Equity investee loss               -             164               -         358 
								
Net income                     $15,357       $12,868          $28,505    $23,320 
  
Basic earnings per share         $0.26         $0.22            $0.49      $0.40 
								
Weighted average shares
 outstanding-basic          58,751,478    57,953,563       58,657,220 57,864,438 
								
Diluted earnings per share       $0.26         $0.22            $0.48      $0.40 
								
Weighted average shares
 outstanding-diluted        59,348,559    58,457,280       59,600,313 58,290,610 
 
 * 1999 income statements exclude a one-time charge incurred in Q2 1999 
 in connection with the terminated PAREXEL merger totaling $5,249 ($3,150 after tax.)


                        COVANCE INC.
                 CONDENSED BALANCE SHEET DATA
             JUNE 30, 1999 AND DECEMBER 31, 1998 
                   (Dollars in thousands)
    
    
                                     June 30,       December 31,
                                       1999          1998
                                           (UNAUDITED)

CONDENSED BALANCE SHEET DATA				
				
Cash and cash equivalents           $25,081       $19,263 
Accounts and unbilled receivables  $211,791      $180,734 
Total Current Assets               $309,363      $274,489 
Total Assets                       $665,925      $593,415 
				
				
Total Current Liabilities          $184,119      $193,001 
Long-term debt                     $199,166      $149,909 
Total Liabilities                  $410,875      $368,400 
Total Stockholders' Equity         $255,050      $225,015 
  
  
				

                       COVANCE INC.
                 CONDENSED CASH FLOW DATA
        
        FOR THE SIX MONTHS ENDED JUNE 30, 1999 AND 1998
                  (Dollars in thousands)
                      (UNAUDITED)
             
             
                                   Six Months Ended June 30
                                       1999          1998
CONDENSED CASH FLOW DATA				
				
 Cash flows from net earnings 
  adjusted for non-cash activity    $52,324       $45,614 
   
 Changes in operating assets
   and liabilities                 (37,607)      (46,534)
   
  Net cash (used in) provided
   by operating activities           14,717         (920)
				
 Capital expenditures              (48,349)      (23,523)
 Contingent purchase price 
  paid in connection with 
  prior acquisitions               (16,128)           -   
  
  Other, net                            564            54 
				
  Net proceeds from debt             50,000         5,000 
				
  Cash provided by stock 
   issued under employee				
   benefit plans                      5,014         2,593 
				
  Net change in cash 
   and cash equivalents               5,818      (16,796)
				
  Cash and cash equivalents, 
   beginning of period               19,263        28,027 
				
  Cash and cash equivalents, 
   end of period                    $25,081       $11,231 
   
   
  SOURCE  Covance Inc.